

# Targeting of Ras-mediated FGF signaling suppresses Pten-deficient skin tumor

Grinu Mathew<sup>a,b,1</sup>, Abdul Hannan<sup>a,b</sup>, Kristina Hertzler-Schaefer<sup>c</sup>, Fen Wang<sup>d</sup>, Gen-Sheng Feng<sup>e,f</sup>, Jian Zhong<sup>g</sup>, Jean J. Zhao<sup>h,i</sup>, Julian Downward<sup>j</sup>, and Xin Zhang<sup>a,b,2</sup>

<sup>a</sup>Department of Ophthalmology, Columbia University, New York, NY 10032; <sup>b</sup>Department of Pathology and Cell Biology, Columbia University, New York, NY 10032; <sup>c</sup>Department of Biology, University of North Carolina, Chapel Hill, NC 27599; <sup>d</sup>Center for Cancer Biology and Nutrition, Institute of Biosciences and Technology, Texas A&M, Houston, TX 77030; <sup>e</sup>Department of Pathology, School of Medicine, University of California, San Diego, La Jolla, CA 92093; <sup>f</sup>Section of Molecular Biology, Division of Biological Sciences, University of California, San Diego, La Jolla, CA 92093; <sup>g</sup>Burke Medical Research Institute, Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, White Plains, NY 10605; <sup>h</sup>Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115; <sup>i</sup>Department of Biochemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115; and <sup>j</sup>Oncogene Biology Laboratory, The Francis Crick Institute, London WC2A 3LY, United Kingdom

Edited by Joseph Schlessinger, Yale University School of Medicine, New Haven, CT, and approved October 4, 2016 (received for review March 17, 2016)

**Deficiency in PTEN (phosphatase and tensin homolog deleted on chromosome 10) is the underlying cause of PTEN hamartoma tumor syndrome and a wide variety of human cancers. In skin epidermis, we have previously identified an autocrine FGF signaling induced by loss of Pten in keratinocytes. In this study, we demonstrate that skin hyperplasia requires FGF receptor adaptor protein Frs2 $\alpha$  and tyrosine phosphatase Shp2, two upstream regulators of Ras signaling. Although the PI3-kinase regulatory subunits p85 $\alpha$  and p85 $\beta$  are dispensable, the PI3-kinase catalytic subunit p110 $\alpha$  requires interaction with Ras to promote hyperplasia in Pten-deficient skin, thus demonstrating an important cross-talk between Ras and PI3K pathways. Furthermore, genetic and pharmacological inhibition of Ras-MAPK pathway impeded epidermal hyperplasia in Pten animals. These results reveal a positive feedback loop connecting Pten and Ras pathways and suggest that FGF-activated Ras-MAPK pathway is an effective therapeutic target for preventing skin tumor induced by aberrant Pten signaling.**

FGF | skin | Ras | Pten | Erk

As a commonly mutated tumor suppressor gene, *PTEN* (phosphatase and tensin homolog deleted on chromosome 10) plays critical roles in tissue homeostasis and cancer development (1). In *PTEN* hamartoma tumor syndrome (PHTS), germline mutations of *PTEN* cause hyperplastic changes in the skin, which manifest into acral keratosis and papilloma (2). Although somatic mutation of *PTEN* is rare in skin lesions, the majority of human actinic keratosis and squamous cell carcinoma (SCC) of the skin exhibited reduced levels of *PTEN*, suggesting that epigenetic or posttranscriptional down-regulation of *PTEN* is an important risk factor in skin tumorigenesis (3–5). Consistent with this, genetic ablation of *Pten* in mouse models readily leads to skin hyperkeratosis, papilloma, and eventually SCC (6–8).

FGF signaling has both pro- and antitumorigenic functions in the skin. Aged animals lacking *Fgfr2b* in the epidermis displayed thickening in the skin and heightened sensitivity to a chemical carcinogen, whereas overexpression of *Fgf7* or *Fgf10*, two cognate ligands of *Fgfr2b*, resulted in epidermal hyperplasia and tumor formation (9, 10). Paracrine *FGFR2* signaling has also been found to be important in mediating the oncogenic activity of *p63*, which is frequently amplified in SCC (11). We recently identified a critical link between *Pten* and FGF signaling, showing that elevated PI3K signaling in *Pten*-deficient epidermis led to a mammalian target of rapamycin (mTOR)-regulated increase in *Fgf10* translation (4). The resulting *Fgf10*-*Fgfr2* signaling in the epidermis was both necessary and sufficient to promote skin tumorigenesis. Interestingly, activating mutations in *FGFR3* and *PIK3CA*, which encode the catalytic subunit of PI3 kinase, have been identified in epidermal nevi and seborrheic keratosis (12, 13). Although these skin lesions have different pathologies from papillomas and SCCs, all of them share the epidermal hyperplasia

phenotype. These observations suggest that *FGFR* and *PI3K* signaling are intimately connected in human skin tumorigenesis.

How FGF signaling promotes skin tumorigenesis is not well understood (14). A myriad of cytoplasmic proteins have been implicated in mediating FGF downstream signaling (15). The most important among them is adaptor protein *Frs2*, which can activate Ras signaling by recruiting *Grb2* and tyrosine phosphatases *Shp2*. In addition, *Gab1* protein can stimulate *PI3K* signaling by direct binding to a *PI3K* regulatory subunit, and *PLC $\gamma$*  proteins can induce *PKC* signaling. Adding to the complexity of the FGF signaling network, there is extensive cross-talk among its downstream pathways. For example, Ras protein can directly bind and activate *PIK3CA* (16). Conversely, some studies indicate that *PI3K*-activated *AKT* may also phosphorylate Ras downstream effector *Raf* to suppress its activity (17, 18). Interestingly, it has been observed that 7,12-Dimethylbenz[*a*]anthracene (DMBA)-12-O-tetradecanoylphorbol-13-acetate (TPA)-induced skin carcinomas in *Pten* heterozygous mice exhibit either *H-ras* activation or a complete loss of *Pten* alleles, but not both (19). The underlying cause for such mutual exclusivity between *Ras* and *Pten* mutations in skin cancer remains unsolved.

In this study, we took a genetic approach to dissect FGF downstream pathways in skin tumorigenesis. Our results show that *Pten*-deficient skin requires *Frs2* and *Shp2*, suggesting that *Frs2/Shp2*-activated Ras signaling may be the critical downstream

## Significance

***PTEN* (phosphatase and tensin homolog deleted on chromosome 10) deficiency causes skin lesions in *PTEN* hamartoma tumor syndrome patients, and has been implicated in hyperkeratosis and squamous cell carcinoma in the general population. In this study, we show that FGF-induced Ras signaling acts in a feedback mechanism to enhance *PI3K* activity and promotes epidermal hyperplasia through the *MAPK* pathway. Genetic and pharmacological targeting of the *FGF*-*Ras*-*MAPK* pathway elicits a strong antiproliferative response. Our finding suggests that *FGF*-*Ras* signaling can be explored for therapeutic intervention to treat epidermal lesions in *PTEN*-related hamartoma and skin cancer.**

Author contributions: G.M. and X.Z. designed research; G.M., A.H., and K.H.-S. performed research; F.W., G.-S.F., J.Z., J.J.Z., and J.D. contributed new reagents/analytic tools; G.M. and X.Z. analyzed data; and G.M. and X.Z. wrote the paper.

The authors declare no conflict of interest.

This article is a PNAS Direct Submission.

<sup>1</sup>Present address: Cancer Biology, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724.

<sup>2</sup>To whom correspondence should be addressed. Email: xz2369@columbia.edu.

This article contains supporting information online at [www.pnas.org/lookup/suppl/doi:10.1073/pnas.1604450113/-DCSupplemental](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1604450113/-DCSupplemental).

effector of FGF signaling. In support of this, although deletion of the p85 regulatory subunit of PI3K had no effect, disruption of the Ras interaction with the p110 $\alpha$  catalytic subunit of PI3K suppressed skin hyperplasia. Furthermore, genetic ablation of the Raf–Mek–Erk signaling cascade blocked tumorigenesis in *Pten*-deficient epidermis. These results show that Ras signaling both enhances PI3K activity to cooperate with *Pten* deletion and also promotes skin hyperplasia by activating the MAPK pathway. Finally, we found that pharmacological inhibition of Erk was sufficient to prevent and even to reverse epidermal hyperplasia induced by *Pten* deletion. These results demonstrate that targeting of MAPK signaling is an effective approach to treat *Pten*-deficient skin lesion.


## Results

### *Frs2 $\alpha$* and *Shp2* Convey FGF Signaling in *Pten*-Deficient Epidermis.


Previous studies have established that epidermal deletion of *Pten* in mouse results in skin lesions that closely mimic human PTHS and the onset of SCC (6–8). Using the *Le-Cre* driver to target keratinocytes in the cheek and the eyelid, we observed similar epidermal hyperplasia in 1-mo-old *Le-Cre;Pten<sup>fllox/fllox</sup>* (*Pten<sup>CKO</sup>*) animals (Fig. 1A). Analysis of this mouse model demonstrated that loss of *Pten* led to increasing expression of *Fgf10* in keratinocytes, which activated *Fgfr2* in an autocrine loop to promote skin tumorigenesis (4). To further determine the mediators of FGF signaling in *Pten*-deficient skin tumor, we genetically ablated the adapter protein *Frs2 $\alpha$* , the predominantly expressed *Frs2* family member, in skin epidermis (Fig. S1A) (20). Histological analysis showed that deletion of *Frs2 $\alpha$*  alone did not cause overt skin abnormality, but the epidermal hyperplasia phenotype was completely suppressed in *Pten<sup>CKO</sup>;Frs2 $\alpha$ <sup>CKO</sup>* animals (Fig. 1A and Fig. S1B and C). Unlike *Pten<sup>CKO</sup>* animals that exhibit significant expansions in both the K14<sup>+</sup> basal layer and the K10<sup>+</sup> suprabasal layer in the epidermis, these two keratinocyte layers in *Pten<sup>CKO</sup>;Frs2 $\alpha$ <sup>CKO</sup>* remained unchanged compared with those of control animals. Consistent with abrogation of the hyperplasia phenotype, the proliferation marker *Ki-67* and basal epidermis marker  $\Delta$ Np63 in *Pten<sup>CKO</sup>;Frs2 $\alpha$ <sup>CKO</sup>* skin also reverted to the wild-type levels. By immunostaining and Western blot analysis, however, we showed that pAKT, pS6, and p4EBP1 levels remained elevated, reflecting the up-regulation of PI3K signaling induced by *Pten* deletion (Fig. 1 and Fig. S1D). As a result, we still observed increased *Fgf10* expression in *Pten<sup>CKO</sup>;Frs2 $\alpha$ <sup>CKO</sup>* skin epidermis (Fig. 1 and Fig. S1E). We recently showed that FGF signaling requires cooperation between *Frs2 $\alpha$*  and *Shp2* to activate Ras signaling in eye development (21, 22). This genetic pathway is apparently conserved in skin lesion, as *Pten<sup>CKO</sup>;Shp2<sup>CKO</sup>* also lacks the epidermal hyperplasia phenotype despite elevated levels of PI3K activity and *Fgf10* expression (Fig. 1 and Fig. S1D). These results suggested that *Frs2 $\alpha$*  and *Shp2* are essential components of the *Pten*–FGF signaling axis in skin hyperplasia.

**Ras Binding to p110 $\alpha$  Enhances PI3K Signaling.** Ras is the downstream target of *Frs2 $\alpha$*  and *Shp2*, and it is also known to interact with PI3 kinase (23). The PI3 kinase consists of two subunits: a regulatory subunit p85, which can be directly stimulated by receptor tyrosine kinases, and a catalytic subunit p110, responsible for lipid phosphorylation. Importantly, the p110 $\alpha$  subunit also contains a Ras-binding domain (RBD), which has been shown to be required for Ras-induced transformation in multiple types of cancers (23). To examine PI3K signaling in the epidermis, we generated a conditional knockout of p85 $\alpha$  and p85 $\beta$ , the two major regulatory subunits of PI3 kinase (24). Surprisingly, we still observed significant facial swelling in adult *Le-Cre;Pten<sup>fllox/fllox</sup>;p85 $\alpha$ <sup>fllox/fllox</sup>;p85 $\beta$ <sup>CKO/CKO</sup>* (*Pten<sup>CKO</sup>;p85<sup>CKO</sup>*) animals (Fig. S2). This is confirmed by histological analysis, which showed similar expansion of the epidermal layers in *Pten<sup>CKO</sup>* and *Pten<sup>CKO</sup>;p85<sup>CKO</sup>* skin.

Because p85 $\alpha$  and p85 $\beta$  subunits of PI3 kinase were dispensable for *Pten*-depleted skin lesion, we next considered whether



**Fig. 1.** *Frs2 $\alpha$*  and *Shp2* mediate FGF signaling in *Pten*-null epidermis. (A) Phenotypic comparison of facial skin in *Le-Cre*, *Pten<sup>CKO</sup>*, *Pten<sup>CKO</sup>;Frs2 $\alpha$ <sup>CKO</sup>*, and *Pten<sup>CKO</sup>;Shp2<sup>CKO</sup>* mice. Rescue of the hyperplasia phenotype was evident in *Pten<sup>CKO</sup>;Frs2 $\alpha$ <sup>CKO</sup>* and *Pten<sup>CKO</sup>;Shp2<sup>CKO</sup>* mice, as shown by H&E and immunostaining for K14/K10, *Ki-67*,  $\Delta$ Np63, and *Fgf10* on transverse sections of facial skin. Arrows point to *Ki-67*<sup>+</sup> cells in the epidermis. Note that pAKT and *Fgf10* remained elevated in both mutants. (Scale bars, 50  $\mu$ m.) (Magnification, Insets: 3 $\times$ .) (B) Immunoblotting analyses showed that expression of *Fgf10* and PI3K downstream targets pAKT and pS6 was unaffected by ablation of *Frs2 $\alpha$* , but pErk was down-regulated.




**Fig. 2.** Ras signaling enhances PI3K-AKT pathway. (A) Four-week-old *Pten*<sup>CKO</sup> and *Pten*<sup>CKO</sup>;*p110*<sup>βCKO</sup> mice displayed hyperplasia in the epidermis (arrows). H&E, K14/K10, and Ki-67 staining in the epidermis showed considerable attenuation of hyperplasia phenotype in *Pten*<sup>CKO</sup>;*p110*<sup>αRBDβCKO</sup> and *Pten*<sup>CKO</sup>;*p110*<sup>αCKOβCKO</sup> mice. (Scale bars, 50 μm.) (Magnification, Insets: 3×.) (B) Immunoblots of mouse facial skin epidermal layer showed that Fgf10, AKT, and ERK signaling were reduced in *Pten*<sup>CKO</sup>;*p110*<sup>αRBDβCKO</sup> and *Pten*<sup>CKO</sup>;*p110*<sup>αCKOβCKO</sup> skin epidermis.

PI3 kinase may be directly stimulated by the Ras-p110α interaction. In *Pten*-deficient skin, the epidermal hyperplasia phenotype requires two PI3K catalytic subunits, p110α and p110β (25). Combined deletion of both *p110*α and *p110*β was shown to completely block skin lesions in the absence of *Pten*. Indeed, we observed that skin hyperplasia was partially reduced in *Le-Cre*;*Pten*<sup>fllox/fllox</sup>;*p110*<sup>βfllox/fllox</sup> (*Pten*<sup>CKO</sup>;*p110*<sup>βCKO</sup>) mice and abolished in *Le-Cre*;*Pten*<sup>fllox/fllox</sup>;*p110*<sup>αfllox/fllox</sup>;*p110*<sup>βfllox/fllox</sup> (*Pten*<sup>CKO</sup>;*p110*<sup>αCKOβCKO</sup>) animals (Fig. 2A and Fig. S3A and B). Taking advantage of a *p110*α allele (*p110*<sup>RBD</sup>) that contains two point mutations to disrupt its Ras-binding activity (23), we generated *Le-Cre*;*Pten*<sup>fllox/fllox</sup>;*p110*<sup>αRBDβCKO</sup>;*p110*<sup>βfllox/fllox</sup> (*Pten*<sup>CKO</sup>;*p110*<sup>αRBDβCKO</sup>) animals. Compared with *Pten*<sup>CKO</sup> mice, the facial skin in *Pten*<sup>CKO</sup>;*p110*<sup>αRBDβCKO</sup> mutants was drastically reduced in thickness, although it was still moderately thicker than *Pten*<sup>CKO</sup>;*p110*<sup>αCKOβCKO</sup> mice (Fig. 2A and Fig. S3A and B). Although *Pten*<sup>CKO</sup>;*p110*<sup>αRBDβCKO</sup> skin epidermis still showed elevated levels of pS6 and p4EBP1, phosphorylation of Erk was reduced to the wild-type level (Fig. 2B and Fig. S3A and C). Interestingly, we observed that *Spry4* and *Dusp7*, two repressors of MAPK signaling, were induced in *p110*<sup>αRBDβCKO</sup>;*p110*<sup>βfllox/fllox</sup> skin keratinocytes treated with *Pten* inhibitor and Cre-expressing adenovirus (Fig. S3D and E). This suggests that Ras-independent activation of p110α may negatively regulate Erk signaling via *Spry4* and *Dusp7*. Finally, analysis of differentiation and proliferation markers K14/K10, Ki-67, and ΔNp63 further confirmed that *Pten*<sup>CKO</sup>;*p110*<sup>αCKOβCKO</sup> mice were resistant to skin hyperplasia induced by *Pten* loss. Immunohistochemistry and Western blot analysis of *Pten*<sup>CKO</sup>;*p110*<sup>αCKOβCKO</sup> skin epidermis showed that pAKT, pS6, and p4EBP1 were reduced compared with those of *Pten*<sup>CKO</sup> samples (Fig. 2B and Fig. S3A). Taken together, these results suggested that Ras signaling directly activates p110α to enhance PI3K signaling, synergizing with *Pten* deletion in epidermal hyperplasia.

#### The MAPK Pathway Is Vital for Skin Hyperplasia Induced by *Pten* Loss.

Loss of *Pten* in keratinocytes has been reported to induce phosphorylation of Erk, the canonical target of Ras-MAPK signaling (6, 8). We similarly observed a consistent increase in the pErk level in *Pten*<sup>CKO</sup> skin epidermis, which was abrogated by deletion of p110α and p110β (Fig. 2B). This raises the possibility that MAPK signaling may be functionally important in *Pten*-null skin tumor. Ras activates the MAPK cascade by initiating the sequential phosphorylation of Raf, Mek, and Erk kinases, which ultimately phosphorylate a diverse array of nuclear and cytoplasmic substrates (26). Among the three *Raf* kinase genes in the mouse genome, *Araf* is ubiquitously expressed, but it also has the lowest kinase activity toward Mek (27). On the other hand, *Braf* and *Craf* can form homo- and heterodimers in a Ras-dependent fashion, which accounts for the majority of Raf kinase activities (26). In fact, previous studies have shown that ablation of *Craf* alone was sufficient to suppress Ras-dependent tumors in the lung and skin (28, 29). We thus generated *Le-Cre*;*Pten*<sup>fllox/fllox</sup>;*Braf*<sup>fllox/fllox</sup>;*Craf*<sup>fllox/fllox</sup> (*Pten*<sup>CKO</sup>;*Braf*<sup>fllox/fllox</sup>;*Craf*<sup>fllox/fllox</sup>) animals to ablate *Braf* and *Craf* in the epidermis. Surprisingly, despite of the moderate reduction of pErk in the epidermis, the skin hyperplasia phenotype was only modestly mitigated in *Pten*<sup>CKO</sup>;*Braf*<sup>fllox/fllox</sup>;*Craf*<sup>fllox/fllox</sup> mice (Fig. 3A and Fig. S4A–C), suggesting that *Braf* and *Craf* were not essential for *Pten*-deficient skin hyperplasia.

Studies in mammals have clearly demonstrated that in certain contexts, Raf could transmit Ras signaling through effectors other than Mek. Conversely, Mek may also function independently of Raf kinases and Erk independently of Mek activity (30–32). This has been supported by phenotypes of various murine Raf, Mek, and Erk kinase knockouts, which resemble each other in some but not all developmental processes. To test if the remaining cascade of the MAPK signaling is still required for skin lesion, we next deleted Mek and Erk kinases in *Le-Cre*;*Pten*<sup>fllox/fllox</sup>;*Mek1*<sup>fllox/fllox</sup>;*Mek2*<sup>KO/KO</sup> (*Pten*<sup>CKO</sup>;*Mek1/2*<sup>CKO</sup>) and *Le-Cre*;*Pten*<sup>fllox/fllox</sup>;*Erk1*<sup>KO/KO</sup>;*Erk2*<sup>fllox/fllox</sup>



**Fig. 3.** MAPK pathway activated by *Pten*-Fgf10 signaling axis is essential for skin hyperplasia. (A) In comparison with *Pten*<sup>CKO</sup> mice, the epidermal hyperplasia phenotype was moderately reduced in *Pten*<sup>CKO</sup>;*BrffCrff*<sup>CKO</sup> and completely abolished in *Pten*<sup>CKO</sup>;*Mek1/2*<sup>CKO</sup> and *Pten*<sup>CKO</sup>;*Erk1/2*<sup>CKO</sup> mice, as shown by H&E of facial epidermis and immunostaining analyses of K14/K10 and *Ki*-67. (Scale bars, 50  $\mu$ m.) (Magnification, *Insets*: 3 $\times$ .) (B) Immunoblotting analyses of the epidermal skin lysate.

(*Pten*<sup>CKO</sup>*Erk1/2*<sup>CKO</sup>) mice, respectively. Staining for K14/K10 showed a drastic shrinkage in epidermal layers, and *Ki*-67 and  $\Delta$ Np63 indices were indistinguishable from those of WT control mice (Fig. 3*A* and Fig. S4*A* and *B*). Notably, deletion of *Mek* and *Erk* did not induce abnormal apoptosis or abrogate the increase in Fgf10, pS6, and p4EBP1 induced by *Pten* deletion (Fig. 3 and Fig. S4*D*). Together, these genetic evidence demonstrate that Ras-MAPK effectors *Mek* and *Erk* are required for mediating the *Pten*-Fgf10-Fgfr signaling axis in skin hyperplasia.

#### Erk Is a Pharmacological Target Critical for *Pten*-Null Skin Hyperplasia.


The striking rescue of the skin hyperplasia phenotype by *Erk* deletion prompted us to investigate whether pharmacological targeting of *Erk* protein in *Pten*<sup>CKO</sup> mice would prevent skin lesion. Wild-type and *Pten*<sup>CKO</sup> mice starting at 3 wk of age were dosed twice daily by intraperitoneal injection with *Erk* inhibitor SCH772984 (25 mg/kg) or vehicle (33). During 2 wk of treatment, whereas vehicle-treated mice showed rapid emergence of hyperplasia, inhibitor-treated animals remained free of lesions (Fig. 4*A–C* and Fig. S1*B*). There was no significant change in body weight between dosed and vehicle-treated mice, but histological analysis showed a substantial decrease in skin thickness in treated mice (Fig. 4*A* and *B*). K14/K10 staining in skin sections from SCH772984-treated mice also confirmed significant suppression of epidermal expansion. Compared with vehicle-treated *Pten*<sup>CKO</sup> mice, drug treatment resulted in a substantial reduction in hyperproliferative cells as shown by *Ki*-67 and  $\Delta$ Np63 staining (Fig. 4*A* and *B*). Lastly, we treated *Pten*<sup>CKO</sup> mice at 5 wk when hyperplasia was already apparent. After 2 wk of treatment, the skin epidermis was drastically reduced in thickness, accompanied by diminished expression of K14/K10, *Ki*-67, and  $\Delta$ Np63 (Fig. S5*A–C*). This effect is likely cell autonomous, as we observed that hyperproliferation induced by *Pten* inhibition was similarly suppressed

by addition of *Erk* inhibitor in mouse keratinocyte cultures (Fig. S5*D*). Hence, pharmacological inhibition of *Erk* signaling could not only inhibit but also reverse lesion formation in *Pten*-deficient epidermis.

#### Discussion

PTEN deficiency causes skin lesions in PHTS patients and promotes hyperkeratosis and SCC (3–5). Based on our previous finding that loss of *Pten* induced FGF signaling in keratinocytes, we investigated the genetic cascade that led to skin hyperplasia. Our results showed that epidermal FGF signaling is transmitted by *Frs2a* and *Shp2*, which are required for Ras activation. In support of the key role of Ras in *Pten*-deficient lesion, genetic disruption of the Ras-PI3K interaction or Ras-MAPK pathway diminished the hyperproliferative effect of *Pten* loss. Pharmacological inhibition of *Erk* also blocked lesion formation in *Pten*-depleted skin (Fig. 4*D*). These results suggest that FGF signaling activates the Ras pathway to cooperate with *Pten* deletion in skin lesion.

Activation of Ras signaling by the *Pten*-FGF axis explains a long-standing conundrum in skin cancer—namely, the mutually exclusive nature of *Ras* and *Pten* mutations in a mouse model of SCC. In the wild-type skin, DMBA-TPA treatment is known to predominantly induce *H-ras* mutations (19). The same treatment on the skin of *Pten*<sup>+/-</sup> mice, however, produced carcinoma that carried either loss-of-heterozygosity mutations in *Pten* or activation mutations in *H-ras*, but not both. Consistent with this, transgenic overexpression of activated *H-ras* did not significantly enhance malignant transformation of skin tumor generated by genetic ablation of *Pten* (8). According to our model of the *Pten*-FGF-Ras signaling cascade, deletion of *Pten* itself is sufficient to induce Ras signaling in skin epidermis, suggesting that there is little additional benefit to induce mutation in the *H-ras* locus. In



**Fig. 4.** Pharmacological targeting of Erk prevents *Pten*-deficient skin lesion. (A and B) Phenotypic comparison of hyperplasia in *Pten<sup>CKO</sup>* mice after pharmacological inhibition of Erk. Administration of Erk inhibitor SCH772984 or vehicle control in *Pten<sup>CKO</sup>* mice started at 3 wk of age and continued to 5 wk of age. SCH772984-treated *Pten<sup>CKO</sup>* mice showed significant reduction in skin thickness, keratinocyte proliferation, and differentiation as observed by K14/K10, K<sub>6</sub>-7, and  $\Delta$ Np63 staining. (Student *t* test: \**P* < 0.001; *n* = 9). (C) Kaplan–Meier curve for *Pten<sup>CKO</sup>* mice treated with inhibitor (red, *n* = 5) or vehicle (black, *n* = 5) only [log rank (Mantel–Cox) test: \**P* < 0.001; *n* = 5]. The appearance of hyperplasia in each animal was considered as an event toward skin lesion. (Scale bar, 50  $\mu$ m.) (Magnification, Insets: 3 $\times$ .) (D) Model of Ras-mediated FGF signaling in promoting epidermal hyperplasia and tumorigenesis in *Pten*-deficient skin. Loss of *Pten* in keratinocytes results in mTORC1-mediated induction of FGF10 to activate *Fgfr2*. This leads to an *Frs2*–*Shp2*–*Ras* signaling cascade that enhances PI3K signaling and stimulates the *Ras*–*Mek*–*Erk* pathway, both of which are critical for epidermal hyperplasia and eventual tumorigenesis. These skin lesions can be effectively inhibited by Erk inhibitor SCH772984, suggesting a therapeutic approach for PHTS.

contrast, further activation of H-ras in *Pten*-null skin may even be counterproductive, as the overall Ras signaling is pushed too high that it could trigger oncogene-mediated senescence.

Our study suggests that Ras signaling also stimulates PI3K signaling in skin keratinocytes. In *Pten*-deficient skin lesions, activity of the PI3K pathway is greatly elevated. Although this originated from the removal of *Pten* as the negative regulator of PI3K signaling, it may also involve a positive regulation of PI3K itself to activate its enzymatic activity (24). The most common mechanism to stimulate PI3K is through its p85 regulatory subunits, whose SH2 domains bind a wide variety of cell-surface receptors or adaptor proteins. In *Pten* mutant skin, however, our results show that deletion of PI3K regulatory subunits *p85 $\alpha/\beta$*  failed to suppress epidermal hyperplasia. Instead, mutation in the RBD of *p110 $\alpha$*  strongly reduced the level of pAKT, resulting in significant mitigation of the hyperplasia phenotype. This is consistent with a previous study in mouse embryonic fibroblast cells, which suggests that direct binding of Ras to the RBD motif of p110 $\alpha$  is required for FGF2 signaling to AKT (23). Furthermore, blocking the Ras binding region of the p110 alpha subunit also interfered with skin tumor formation induced by H-Ras and lung adenomas driven by *Kras* (34). Notably, deletion of *p110 $\beta$*  alone also moderately attenuated the *Pten* epidermal phenotype (25). Although p110 $\beta$  does not directly interact with Ras, it can be stimulated by *Rac1* and *Cdc42*, two small Rho GTPases downstream to both receptor tyrosine kinase and G protein-coupled receptor (GPCR) signaling (35). Given this evidence, our work suggests that FGF-mediated positive feedback to the PI3K–Akt pathway is an important oncogenic mechanism in *Pten*-deficient skin.

Perturbations in the RAS–MAPK pathway are common in skin tumors (36). Consistent with previous studies, we observed that the level of pErk was also elevated in *Pten*-deficient keratinocytes (6, 8). Contrary to previous studies that indicated a crucial role of *Craf* in Ras-driven lung and skin cancer, we found that deletion of both *Braf* and *Craf* only resulted in modest reduction of epidermal hyperplasia (28, 29). Nevertheless, ablation of either *Mek* or *Erk* completely suppressed hyperplasia in *Pten*-deficient skin. Importantly, we showed that SCH772984, a small molecule inhibitor of ERK, was not only effective in preventing epidermal hyperplasia induced by *Pten* loss; it could also reverse the hyperplasia phenotype after skin lesions were already

established. Significant efforts are under way to develop pharmacological inhibitors against the RAS–MAPK pathway, some of which are already approved for clinical use. Our results suggest that FGF–Ras signaling can be explored for therapeutic intervention to treat skin lesions in PHTS and other PTEN-related conditions.

## Methods

**Mice.** Mice carrying *Frs2 $\alpha^{flox}$* , *Shp2 $^{flox}$* , *p110 $\alpha^{flox}$* , *p110 $\beta^{flox}$* , *p110 $\alpha^{RBD}$*  (JAX strain name - B6.129S7(Cg)-*Pik3ca<sup>tm1jdc</sup>*), *Erk1 $^{KO}$* , *Erk2 $^{flox}$* , *Mek1 $^{flox}$* , *Mek2 $^{KO}$* , *Braf $^{flox}$* , and *Craf $^{flox}$*  alleles were bred and genotyped as described (23, 37–42). From Lewis Cantley's laboratory, Weill Cornell Medical College, New York, we obtained the floxed allele of *p85 $\alpha$*  (*Pik3r1*) and a knockout allele of *p85 $\beta$*  (*Pik3r2*), two genes that encode the main regulatory subunits of class IA PI3K, *p85 $\alpha$* /*p55 $\alpha$* /*p50 $\alpha$*  and *p85 $\beta$* , respectively (43, 44). *Le-Cre* mice were kindly provided by Ruth Ashery-Padan, Tel Aviv University, Tel Aviv, Israel (45). *Pten $^{flox}$*  mice were obtained from Jackson Laboratory (46). All animal experiments were performed according to institutional guidelines and approved by the Columbia University Institutional Animal Care and Use Committee (IACUC).

**Keratinocyte Culture.** Mouse keratinocytes were isolated and cultured from P0 pups following protocol as described (4). The cells were maintained in keratinocyte-specific basal media from CELLnTEC. A total of  $1 \times 10^5$  wild-type keratinocytes per well were plated in six-well culture plates and treated with vehicle, *Pten* inhibitor (VO-OHpic trihydrate; 400 nM), Erk inhibitor (U0126; 10  $\mu$ M), or both. Total cell count posttreatment was recorded with an automated cell counter at day 2, 4, 6, and 8 using the Trypan blue dye exclusion test.

**Histology and Immunohistochemistry.** Briefly, after the mice were euthanized, skin from the cheek continuing through and around the eyelids were removed and placed in 4% (wt/vol) PFA overnight. The skin samples collected were either paraffin- or cryo-embedded and sectioned at 8–10- $\mu$ m thickness. H&E staining was performed using a Leica Automatic Stainer and immunohistochemistry following antigen retrieval in sodium citrate buffer as described (47). Antibodies used are K<sub>6</sub>-7 (BD Pharmingen; Clone B56; 1:100),  $\Delta$ Np63 (Biolegend; Poly6190; 1:500), Keratin 10 (Covance; PRB-159P; 1:200), Keratin 14 (Thermo Scientific; LL002; 1:100), phospho-4E-BP1 (Cell Signaling Technology; 236B4; 1:500), phospho-S6 (Cell Signaling Technology; D57.2.2E; 1:500), phospho-Akt<sup>S473</sup> (Cell Signaling Technology; D9E; 1:100), Fgf10 (Millipore; ABN44; 1:100), pErk (Cell Signaling Technology; E10; 1:1000), and Erk (Santa Cruz; H-72; 1:3000).

K10, K14, K<sub>6</sub>-7, and  $\Delta$ Np63 indices were calculated by counting the number of positively stained nuclei within 100- $\mu$ m-long skin tissue sections and compared with wild-type controls; one-way ANOVA was performed to determine *P* value.

**Western Blot.** Immediately after mice were euthanized, hair around the face was removed using Nair hair removal cream. Skin around the cheek and eyelid area was dissected out in one piece, snap-frozen, and stored at  $-80^{\circ}\text{C}$  until use. The dissected skin samples were then carefully scraped with a curette to selectively remove only the epidermal layer. Scrapings were then lysed in RIPA buffer containing protease inhibitors. Protein concentrations in the lysates were determined using the BCA kit. Equal amounts of the lysates were loaded and separated on 10–12% (wt/vol) SDS/PAGE gels before being transferred onto a PVDF membrane. The blots were stained with primary antibodies overnight and visualized using IRDye-linked secondary antibody.

**Quantitative Real-Time PCR.** Total RNA was extracted from skin and keratinocyte samples and converted to cDNA using SuperScriptIII RT kit as described (48). Primers used for quantitative PCR analysis are as follows: *Spry2*, CAATGGCAGGCAATGTATG and GGAGGAAGTGAGCAGAGGTG; *Spry4*, GCAGCGTCCCTGTGAATCC and TCTGTCAATGGGTAAGATGGT; *Dusp6*, CGTGTGGACCTTGGTGG and ACACGGACAGAACGGATCTC; *Dusp7*, GTGCTGCTCTACGACGAGG and TGAACCACCTTGGAGGTAGT; and *Gapdh*, AGGTCGGTGAACGGATTG and TGTAGACCATGTAGTTGAGGTCA.

**Inhibitor Treatment.** *Pten*<sup>CKO</sup> mice were injected intraperitoneally with SCH772984 (Chemitec) at a 25-mg/kg dosage twice daily or with vehicle control for a period of 14 d as described (33, 49). A SCH772984 stock solution of 10 mg/mL was prepared by dissolving 11.9 mg SCH772984 in 986  $\mu\text{L}$  20% hydroxypropyl  $\beta$  cyclodextrin and 14.3  $\mu\text{L}$  2N NaOH, followed by continuous vortexing/sonication for 5 min and pH adjustment to 4.5. Before dosing, SCH772984 solution was brought to room temperature ( $\sim 30$  min). The mice were monitored daily for changes in hyperplasia phenotype, and facial epidermal tissue was harvested and used for histological analysis after the trial period.

**ACKNOWLEDGMENTS.** The authors thank Drs. Lewis Cantley and Ruth Ashery-Padan for mice, and the Columbia Dermatology Core Facility for technical support. The work was supported by a pilot grant from Columbia Skin Diseases Research Center, and NIH Grants EY017061, EY018868, and EY025933 (to X.Z.), and EY022409 (to J.J.Z.). The Columbia Dermatology Core Facility is supported by NIH Core Grant 5P30AR044535. The Columbia Ophthalmology Core Facility is supported by NIH Core Grant 5P30EY019007 and unrestricted funds from Research to Prevent Blindness. X.Z. is supported by the Jules and Doris Stein Research to Prevent Blindness Professorship.

- Salmena L, Carracedo A, Pandolfi PP (2008) Tenets of PTEN tumor suppression. *Cell* 133(3):403–414.
- Eng C (2003) PTEN: One gene, many syndromes. *Hum Mutat* 22(3):183–198.
- Darido C, et al. (2011) Targeting of the tumor suppressor GRHL3 by a miR-21-dependent proto-oncogenic network results in PTEN loss and tumorigenesis. *Cancer Cell* 20(5):635–648.
- Hertzier-Schaefer K, et al. (2014) Pten loss induces autocrine FGF signaling to promote skin tumorigenesis. *Cell Reports* 6(5):818–826.
- Ming M, et al. (2011) PTEN positively regulates UVB-induced DNA damage repair. *Cancer Res* 71(15):5287–5295.
- Suzuki A, et al. (2003) Keratinocyte-specific Pten deficiency results in epidermal hyperplasia, accelerated hair follicle morphogenesis and tumor formation. *Cancer Res* 63(3):674–681.
- Squarize CH, Castilho RM, Gutkind JS (2008) Chemoprevention and treatment of experimental Cowden's disease by mTOR inhibition with rapamycin. *Cancer Res* 68(17):7066–7072.
- Yao D, et al. (2006) PTEN loss promotes rasHa-mediated papillomatogenesis via dual up-regulation of AKT activity and cell cycle deregulation but malignant conversion proceeds via PTEN-associated pathways. *Cancer Res* 66(3):1302–1312.
- Grose R, et al. (2007) The role of fibroblast growth factor receptor 2b in skin homeostasis and cancer development. *EMBO J* 26(5):1268–1278.
- Guo L, Yu QC, Fuchs E (1993) Targeting expression of keratinocyte growth factor to keratinocytes elicits striking changes in epithelial differentiation in transgenic mice. *EMBO J* 12(3):973–986.
- Ramsey MR, et al. (2013) FGFR2 signaling underlies p63 oncogenic function in squamous cell carcinoma. *J Clin Invest* 123(8):3525–3538.
- Hafner C, et al. (2007) Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern. *Proc Natl Acad Sci USA* 104(33):13450–13454.
- Logie A, et al. (2005) Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. *Hum Mol Genet* 14(9):1153–1160.
- Carter EP, Fearon AE, Grose RP (2015) Careless talk costs lives: Fibroblast growth factor receptor signalling and the consequences of pathway malfunction. *Trends Cell Biol* 25(4):221–233.
- Beenken A, Mohammadi M (2009) The FGF family: Biology, pathophysiology and therapy. *Nat Rev Drug Discov* 8(3):235–253.
- Rodrguez-Viciano P, et al. (1994) Phosphatidylinositol-3-OH kinase as a direct target of Ras. *Nature* 370(6490):527–532.
- Guan KL, et al. (2000) Negative regulation of the serine/threonine kinase B-Raf by Akt. *J Biol Chem* 275(35):27354–27359.
- Rommel C, et al. (1999) Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. *Science* 286(5445):1738–1741.
- Mao JH, et al. (2004) Mutually exclusive mutations of the Pten and Ras pathways in skin tumor progression. *Genes Dev* 18(15):1800–1805.
- Gotoh N (2008) Regulation of growth factor signaling by FRS2 family docking/scaffold adaptor proteins. *Cancer Sci* 99(7):1319–1325.
- Cai Z, et al. (2013) Deficient FGF signaling causes optic nerve dysgenesis and ocular coloboma. *Development* 140(13):2711–2723.
- Li H, et al. (2014) Frs2 $\alpha$  and Shp2 signal independently of Gab2 to mediate FGF signaling in lens development. *J Cell Sci* 127(Pt 3):571–582.
- Gupta S, et al. (2007) Binding of ras to phosphoinositide 3-kinase p110 $\alpha$  is required for ras-driven tumorigenesis in mice. *Cell* 129(5):957–968.
- Yuan TL, Cantley LC (2008) PI3K pathway alterations in cancer: Variations on a theme. *Oncogene* 27(41):5497–5510.
- Wang Q, et al. (2013) Spatially distinct roles of class Ia PI3K isoforms in the development and maintenance of PTEN hamartoma tumor syndrome. *Genes Dev* 27(14):1568–1580.
- Matallanas D, et al. (2011) Raf family kinases: Old dogs have learned new tricks. *Genes Cancer* 2(3):232–260.
- Marais R, Light Y, Paterson HF, Mason CS, Marshall CJ (1997) Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic Ras and tyrosine kinases. *J Biol Chem* 272(7):4378–4383.
- Blasco RB, et al. (2011) c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. *Cancer Cell* 19(5):652–663.
- Ehrenreiter K, et al. (2009) Raf-1 addition in Ras-induced skin carcinogenesis. *Cancer Cell* 16(2):149–160.
- Galabova-Kovacs G, et al. (2006) ERK and beyond: Insights from B-Raf and Raf-1 conditional knockouts. *Cell Cycle* 5(14):1514–1518.
- Murakami MS, Morrison DK (2001) Raf-1 without MEK? *Sci STKE* 2001(99):pe30.
- Tapinos N, Rambukkana A (2005) Insights into regulation of human Schwann cell proliferation by Erk1/2 via a MEK-independent and p56Lck-dependent pathway from leprosy bacilli. *Proc Natl Acad Sci USA* 102(26):9188–9193.
- Morris EJ, et al. (2013) Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. *Cancer Discov* 3(7):742–750.
- Castellano E, et al. (2013) Requirement for interaction of PI3-kinase p110 $\alpha$  with RAS in lung tumor maintenance. *Cancer Cell* 24(5):617–630.
- Fritsch R, et al. (2013) RAS and RHO families of GTPases directly regulate distinct phosphoinositide 3-kinase isoforms. *Cell* 153(5):1050–1063.
- Green CL, Khavari PA (2004) Targets for molecular therapy of skin cancer. *Semin Cancer Biol* 14(1):63–69.
- Bard-Chapeau EA, et al. (2005) Deletion of Gab1 in the liver leads to enhanced glucose tolerance and improved hepatic insulin action. *Nat Med* 11(5):567–571.
- Lin Y, Zhang J, Zhang Y, Wang F (2007) Generation of an Frs2 $\alpha$  conditional null allele. *Genesis* 45(9):554–559.
- Zhang EE, Chapeau E, Hagihara K, Feng GS (2004) Neuronal Shp2 tyrosine phosphatase controls energy balance and metabolism. *Proc Natl Acad Sci USA* 101(45):16064–16069.
- Newbern JM, et al. (2011) Specific functions for ERK/MAPK signaling during PNS development. *Neuron* 69(1):91–105.
- Zhong J, et al. (2007) Raf kinase signaling functions in sensory neuron differentiation and axon growth in vivo. *Nat Neurosci* 10(5):598–607.
- Newbern J, et al. (2008) Mouse and human phenotypes indicate a critical conserved role for ERK2 signaling in neural crest development. *Proc Natl Acad Sci USA* 105(44):17115–17120.
- Luo J, et al. (2005) Class IA phosphoinositide 3-kinase regulates heart size and physiological cardiac hypertrophy. *Mol Cell Biol* 25(21):9491–9502.
- Ueki K, et al. (2002) Increased insulin sensitivity in mice lacking p85 $\beta$  subunit of phosphoinositide 3-kinase. *Proc Natl Acad Sci USA* 99(1):419–424.
- Ashery-Padan R, Marquardt T, Zhou X, Gruss P (2000) Pax6 activity in the lens primordium is required for lens formation and for correct placement of a single retina in the eye. *Genes Dev* 14(21):2701–2711.
- Lesche R, et al. (2002) Cre/loxP-mediated inactivation of the murine Pten tumor suppressor gene. *Genesis* 32(2):148–149.
- Cai Z, et al. (2011) Loss of Shp2-mediated mitogen-activated protein kinase signaling in Muller glial cells results in retinal degeneration. *Mol Cell Biol* 31(14):2973–2983.
- Carbe C, et al. (2013) An allelic series at the paired box gene 6 (Pax6) locus reveals the functional specificity of Pax genes. *J Biol Chem* 288(17):12130–12141.
- Morris V, Kopetz S (2013) BRAF inhibitors in clinical oncology. *F1000Prime Rep* 5:11.